These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23250707)

  • 21. Preformulation study of a poorly water-soluble drug, alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol: selection of the base for dosage form design.
    Serajuddin AT; Sheen PC; Mufson D; Bernstein DF; Augustine MA
    J Pharm Sci; 1986 May; 75(5):492-6. PubMed ID: 3735089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH.
    Li S; Wong S; Sethia S; Almoazen H; Joshi YM; Serajuddin AT
    Pharm Res; 2005 Apr; 22(4):628-35. PubMed ID: 15846471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An automated approach to salt selection for new unique trazodone salts.
    Ware EC; Lu DR
    Pharm Res; 2004 Jan; 21(1):177-84. PubMed ID: 14984273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preparation and characterisation of a range of diclofenac salts.
    O'Connor KM; Corrigan OI
    Int J Pharm; 2001 Sep; 226(1-2):163-79. PubMed ID: 11532579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancing the Stability, Solubility, and Antioxidant Activity of Cinchonine through Pharmaceutical Cocrystallization.
    Zhou Y; Tu Y; Yang J; Qian K; Liu X; Fu Q; Xu X; Chen S
    Pharm Res; 2024 Jun; 41(6):1257-1270. PubMed ID: 38844745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate.
    Seo JH; Park JB; Choi WK; Park S; Sung YJ; Oh E; Bae SK
    Drug Des Devel Ther; 2015; 9():3961-8. PubMed ID: 26251575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The crystalline salt form of a selected candidate drug showed photo-, thermal- and humidity induced form transitions.
    Sigfridsson K; Lindsjö M; Paulsson S
    Eur J Pharm Sci; 2019 Feb; 128():128-136. PubMed ID: 30502453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An investigation into the influence of counterion on the properties of some amorphous organic salts.
    Towler CS; Li T; Wikström H; Remick DM; Sanchez-Felix MV; Taylor LS
    Mol Pharm; 2008; 5(6):946-55. PubMed ID: 19434850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations.
    Williams HD; Ford L; Lim S; Han S; Baumann J; Sullivan H; Vodak D; Igonin A; Benameur H; Pouton CW; Scammells PJ; Porter CJH
    J Pharm Sci; 2018 Jan; 107(1):203-216. PubMed ID: 28549907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Lipophilic Salt Form to Enhance the Lipid Solubility and Certain Biopharmaceutical Properties of Lapatinib.
    Singh N; Chakravarti R; Das A; Gupta S; Ghosh D; Datta P
    Mol Pharm; 2024 Aug; 21(8):3921-3935. PubMed ID: 38935681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular salts and co-crystals of mirtazapine with promising physicochemical properties.
    Sarkar A; Rohani S
    J Pharm Biomed Anal; 2015 Jun; 110():93-9. PubMed ID: 25818704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compound selection for development - is salt formation the ultimate answer? Experiences with an extended concept of the "100mg approach".
    Korn C; Balbach S
    Eur J Pharm Sci; 2014 Jun; 57():257-63. PubMed ID: 24036162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Supramolecular structures and physicochemical properties of norfloxacin salts.
    Xu Y; Jiang L; Mei X
    Acta Crystallogr B Struct Sci Cryst Eng Mater; 2014 Aug; 70(Pt 4):750-60. PubMed ID: 25080254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salt form selection and characterization of LY333531 mesylate monohydrate.
    Engel GL; Farid NA; Faul MM; Richardson LA; Winneroski LL
    Int J Pharm; 2000 Apr; 198(2):239-47. PubMed ID: 10767572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of counterions on the properties of amorphous atorvastatin salts.
    Sonje VM; Kumar L; Puri V; Kohli G; Kaushal AM; Bansal AK
    Eur J Pharm Sci; 2011 Nov; 44(4):462-70. PubMed ID: 21907794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Situ Salification in Polar Solvents: a Paradigm for Enabling Drug Delivery of Weakly Ionic Drugs as Amorphous Solid Dispersion.
    Nair R; Lamare I; Tiwari NK; Ravi PR; Pillai R
    AAPS PharmSciTech; 2018 Jan; 19(1):326-337. PubMed ID: 28721630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crystallinity, hygroscopicity and dissolution of moricizine hydrochloride hemihydrate.
    Wu LS; Gerard C; Koval C; Rowe S; Hussain MA
    J Pharm Biomed Anal; 1994 Aug; 12(8):1043-6. PubMed ID: 7819378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of chloride ion on dissolution of different salt forms of haloperidol, a model basic drug.
    Li S; Doyle P; Metz S; Royce AE; Serajuddin AT
    J Pharm Sci; 2005 Oct; 94(10):2224-31. PubMed ID: 16136556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diclofenac salts. III. Alkaline and earth alkaline salts.
    Fini A; Fazio G; Rosetti F; Angeles Holgado M; Iruín A; Alvarez-Fuentes J
    J Pharm Sci; 2005 Nov; 94(11):2416-31. PubMed ID: 16200614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.